Major milestones in 2025
A year of ground-breaking achievements
Celebrating 80 years of innovation and our focus on medical dermatology
Portfolio
01
Ebglyss® Strong growth and expanded presence across multiple countries.
- €110.8M net sales in 2025, strong launch
- 1 in 5 eligible EU5 patients started treatment
- Over 9,000 patients treated.
- Presence expanded to 16 countries
02
March 2025
- Presented pipeline and real-world data on dermatology treatments at AAD and ICD
- Highlighted clinical results for key therapies and early well-being findings in psoriasis
- Reinforced focus on holistic patient care and new clinical endpoints
03
September 2025
- Presented new clinical and real-world data at EADV 2025 on key dermatology treatments, including lebrikizumab, tildrakizumab and LAD191
- Shared long-term results from the POSITIVE study, highlighting the use of the WHO-5 Well-Being Index in psoriasis
Collaboration
01
At the 2025 JPMorgan Healthcare Conference, the company positioned 2025 as the launch of a new era of sustained double-digit growth through 2030, underpinned by biologics leadership and increased R&D investment.
January 2025
02
Gathered experts at the 16th Skin Academy to advance knowledge in medical dermatology.
March 2025
03
Launched the “Hats On Challenge” with BioFrontera to raise awareness and support for actinic keratosis.
May 2025
04
Selected a second dermatology target in its generative AI collaboration with Absci, advancing antibody design for challenging drug targets.
August 2025
05
Contributed to the 70th SEFH National Congress, including a symposium on AI in patient follow-up.
September 2025
06
Launch of the “The Deeper Truth About Psoriasis” campaign in collaboration with IFPA.
September 2025
07
ImmunoSkin brought together experts to advance the science and treatment of inflammatory skin conditions.
November 2025
Purpose
01
Recognised as a Top Employer for 17 consecutive years in Spain and for the first time in Germany.
January 2025
02
Reduced water consumption in Spain by 16%, advancing towards a 25% reduction target by 2030.
March 2025
03
Jon Uguzne Garay appointed Chief Financial Officer(effective August 2025).
March 2025
04
Carlos Gallardo elected EFPIA Second Vice-President for a two-year mandate.
June 2025
05
Joined EFA, GlobalSkin and AADA for World Atopic Dermatitis Day with a global awareness campaign featuring patient stories.
September 2025
06
Lidia Martín Pereda appointed Chief Marketing Officer in October 2025
October 2025
07
Achieved 2nd position in MERCO Salud 2025 ranking for dermatology and ranked 4th for innovation in dermatology in Spain
December 2025